INDONESIA CURRENT PROJECTED 2050 COUNTRY OVERVIEW

Similar documents
JAPAN CURRENT PROJECTED 2050 COUNTRY OVERVIEW

CHINA CURRENT PROJECTED 2050 COUNTRY OVERVIEW

SCORECARD Questionnaire September 2012

OSTEOPOROSIS IN INDONESIA

EU Osteoporosis Report SWEDEN

EU Osteoporosis Report CYPRUS

EU Osteoporosis Report AUSTRIA

EU Osteoporosis Report MALTA

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Assessment and Treatment of Osteoporosis Professor T.Masud

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Management of postmenopausal osteoporosis

Audit on follow-up of patients with primary Osteoporosis

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

An audit of osteoporotic patients in an Australian general practice

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Quality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture

Osteoporosis/Fracture Prevention

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Osteoporosis. Skeletal System

Osteoporosis. Overview

Prevention of Osteoporotic Hip Fracture

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals

FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment

Submission to the National Institute for Clinical Excellence on

Osteoporosis: A Tale of 3 Task Forces!

FRiSCy Oxford Fracture Prevention Service

Clinical Practice. Presented by: Internist, Endocrinologist

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Download slides:

Clinician s Guide to Prevention and Treatment of Osteoporosis

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above

Osteoporosis challenges

1

Bone density scanning and osteoporosis

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

Pharmacy Management Drug Policy

Training Course in Sexual and Reproductive Health Research Geneva, February Osteoporosis. Prof René Rizzoli M.D.

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Osteoporosis Agents Drug Class Prior Authorization Protocol

Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness

Understanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.

Prevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

Updates in Osteoporosis

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Osteoporosis Clinical Guideline. Rheumatology January 2017

AACE/ACE Osteoporosis Treatment Decision Tool

An Update on Osteoporosis Treatments

Differentiating Pharmacological Therapies for Osteoporosis

Treatment of Osteoporosis: IHFD 6 th March 2015

Clinical Specialist Statement Template

Osteoporosis Update: Keys to Improving Diagnosis and Preventing Fractures

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Pharmacy Management Drug Policy

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Osteoporosis: Addressing the Unmet Need

Osteoporosis: A Tale of 3 Task Forces!

NATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES

Pharmacy Management Drug Policy

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

Recent advances in the management of osteoporosis

Page 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis

Forteo (teriparatide) Prior Authorization Program Summary

Pathway from Fracture or Risk Factor to Treatment

IOF TOOLKIT IOF COMPENDIUM OF OSTEOPOROSIS. Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

Building Bone Density-Research Issues

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Summary of the risk management plan by product

BEST PRACTICE FRAMEWORK QUESTIONNAIRE

International Journal of Health Sciences and Research ISSN:

FINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY

Outline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD

Study of secondary causes of male osteoporosis

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

The Glasgow UK Experiment: What a Working System Can Deliver

Screening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement

Page 1

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime

Cortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly

WHAT NONPHYSICIAN PROVIDERS CAN DO FOR YOUR FRAGILITY FRACTURE SERVICE

Osteoporosis after Spinal Cord Injury

Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper

New Developments in Osteoporosis: Screening, Prevention and Treatment

Transcription:

Indonesia INDONESIA COUNTRY OVERVIEW The Indonesian population is epected to grow by 20% over the net four decades, from 251 million in 2013 to 300 million in 2050. Life epectancy is likely to reach 80 years by 2050, an 11% increase from the current 72 years (Figure 1). The most dramatic increase is predicted to be in those d over 50 and 70 years, with estimates showing that by 2050 the population in these groups will grow by 135% to 113 million and by 294% to 40.8 million, respectively. By 2050, those at most risk for osteoporosis, i.e. men and women d over 50 years, will make up over one-third of the total Indonesian population (Figure 2) 1. FIGURE 1 Life epectancy in Indonesia CURRENT Population 251 million Aged over 50 years 19% Life epectancy 72 years Hip fracture incidence per year 119/100,000 Cost per hip fracture 5,000 9,000 USD Number of DXA per million population < 0.1 Fracture liaison services not implemented PROJECTED 2050 Population 300 million Aged over 50 years 38% Life epectancy 80 years 82 80 78 76 FIGURE 1 Population projection for Indonesia 74 72 350 total 50+ 70+ 2013 2025 2050 300 250 State of osteoporosis/osteopenia One of the few studies on bone mineral density (BMD) levels and osteoporosis prevalence (T score < -2.5) in the Indonesian population was conducted in 2006. Results found that the prevalence of osteoporosis in women d between 50 80 years was 23% and between 70 80 years was 53% 2. Prevalence of osteoporosis also increased in men, where BMD decreases of 10 20% between the s of 20 39 years and 70 79 years were shown; however the risk for men was 4-times less than the risk for women 2. million 200 150 100 50 2013 2025 2050 1

FIGURE 3 Spine and femur BMD in Indonesian men and women MEN WOMEN 1.2 1.2 BMD (g/cm 2 ) 1.0 0.8 BMD (g/cm 2 ) 1.0 0.8 0.6 20-29 30-39 40-49 50-59 60-69 70-79 20-29 30-39 40-49 50-59 60-69 70-79 80-89 SOURCE Tirtarahardja Gunawan, Setyohadi Bambang, Zhou Weynand Q. Bone Mineral Density Reference Values for Indonesian Men and Women. ASBMR presentation slide. 2006. The graphs shown in Figure 3 and Figure 4 were reported in a study by Tirtarahardja et al., Bone Mineral Density Reference Values for Indonesian Men and Women, and demonstrate the decreasing BMD values and increasing osteoporosis prevalence in Indonesians as they 2. FIGURE 4 Osteoporosis prevalence in Indonesian men and women Lifestyle Of the 251 million people in Indonesia, slightly more than half (51%) of the people live in urban areas (Figure 5) 3. 60 50 Level of awareness The Indonesian Healthy Bone Foundation, known as PERWATUSI, is a not-for-profit organization promoting awareness about osteoporosis throughout Indonesia. Established in 2002, the organization has grown to 26 branches throughout the country. Programmes promoted by PERWATUSI include: prevalence (%) 40 30 20 10 Training of instructors in eercises for bone health Educating about prevention and rehabilitation Distributing materials and books on osteoporosis Conducting seminars and symposia for lay people Epanding reach throughout Indonesia through opening more branches 50-80 60-80 70-80 50-80 60-80 70-80 WOMEN MEN SOURCE Tirtarahardja Gunawan, Setyohadi Bambang, Zhou Weynand Q. Bone Mineral Density Reference Values for Indonesian Men and Women. ASBMR presentation slide. 2006. 2

FIGURE 5 Urban versus rural population in Indonesia 3 urban rural According to hospital data, costs of treating hip fractures vary between private and public hospitals. It costs approimately 1,000 2,000 USD less to receive treatment privately and patients spend less time in the hospital (Table 1). FRACTURE REGISTRIES FRACTURE RATES Hip fracture The IOF hip fracture incidence map indicates Indonesian hip fracture rates of 119/100,000 per year in men and women 4. Another study estimated that there were 38,618 hip fractures that occurred in 2010 with approimately half of those occurring in individuals with T-scores <-2.5 SD 5. The large hospitals in the urban areas of Indonesia estimate that the aver waiting time for surgery, after hip fracture, is about 1 2 days and approimately 75 90% are mand surgically. It is likely these figures are less favourable in the rural areas. Other fragility fractures Data not provided. Vertebral fractures 49% 51% Fracture registries in Indonesia are organized at the hospital level in both the public and private sector, and each hospital is required to submit a fracture report to the Ministry of Health every three months. These reports include all types of fractures in patients of all s. Approimately 43,000 hip fractures were reported in 2010 for men and women d over 40 years (Table 2). TABLE 2 Hospital hip fracture registry in Indonesia, 2010 data AGE (YEARS) WOMEN MEN 40-50 1736 1794 51-60 2925 2377 61-75 14,350 4352 75+ 11,655 3813 FRACTURE LIAISON SERVICES There are currently no fracture liaison services in Indonesia. SPECIALISTS RESPONSIBLE FOR OSTEOPOROSIS Data not provided. COST OF FRACTURE TABLE 1 Hip fracture in Indonesia HOSPITAL COSTS PER HIP FRACTURE (USD) AVERAGE HOSPITAL BED DAYS Private $7,000 9,000 5 14 Public $3,000 5,000 11 16 SURGICALLY TREATED 70% 90% The primary care physicians (family doctors/general physicians/geriatricians/internists) are primarily responsible for managing osteoporosis patients in Indonesia and look after most of the patients with the disease. Speciality physicians also see osteoporosis patients and some receive special training as part of their medical curriculum including: orthopaedists, rheumatologists, endocrinologists and gynaecologists. Other physicians also take part in the manment of osteoporosis including sports medicine specialists, nutritionists and clinical pharmacologists. 3

GOVERNMENT POLICIES Osteoporosis as a documented national health priority Osteoporosis is not officially a national health priority (NHP) in Indonesia. Some activity was seen in that osteoporosis was recognized by the Ministry of Health in 2006 as an NHP. However, since little action has been taken, osteoporosis was recently removed from the health priorities. To promote the importance of osteoporosis at the government level, the Indonesian Woman Leaders Roundtable was formed in 2005. This group of women pushes the government to include osteoporosis as a priority health problem; members include a senior journalist, a former minister, a former member of parliament, and other respected senior citizens. Guidelines The guidelines Panduan Penatalaksanaan Osteoporosis were published in 2010 by the Indonesian Osteoporosis Association (Perhimpunan Osteoporosis Indonesia: PEROSI). Audit and quality indicator systems At present, there are no audit and quality indicator systems in place for osteoporosis treatment. TREATMENT Access to health care in Indonesia can be challenging due to the geographical dispersion of the islands, the low ratio of health-care providers to population and the concentration of health-care services in the urban areas. Cover for care is mostly private and reimbursement is limited to treatment, and thus does not include prevention. Currently, Indonesia is working toward providing universal health-care cover, but is not quite there yet. Until then, just over half of the population have some form of health insurance leaving the other half with difficulties accessing and paying for medical services 6. When treating osteoporosis, bisphosphonates are designated as the first-line treatment but are not reimbursed. In the public sector, calcium supplements only are reimbursed at 100% and zoledronic acid is reimbursed but only for the treatment of metastatic bone disease (Table 3). DIAGNOSTICS Access to dual-energy X-ray absorptiometry (DXA) in Indonesia is limited especially since most machines are located in the cities and just under half of the population live in rural areas. It has been estimated that there are about 65 DXA instruments in Indonesia, which equates to less than 0.1 DXA instruments per million individuals 7. For those who can access DXA, the waiting time is generally 1 day and it costs approimately 54 USD. The lack of reimbursement is a barrier to access and so scans are generally limited to those who can afford private TABLE 3 Treatments available in Indonesia and reimbursement levels Risedronate Alendronate Ibandronate Zoledronic acid Clodronate Pamidronate Raloifene Bazedoifene Denosumab Strontium Ranelate Teriparatide PTH (1-84) Vitamin D/Ca supplements Calcitonin Hormone Replacement Therapy Testosterone Alfacalcidol Calcitriol **not available YES NO ** IF YES, % REIMBURSED only for Metastatic Bone Disease 100% 4

insurance. Ultrasound is slightly more accessible with no waiting time or associated cost and is mainly offered in the commercial sector by pharmaceutical companies to promote their products (Table 4). TABLE 4 Diagnostics access and cost in Indonesia DXA ULTRASOUND Waiting time (d) immediate immediate Cost (USD) $54 free Is it reimbursed? no n/a Is reimbursement a barrier to access to treatment? yes n/a REFERENCES 1. United States Census Bureau 2013, Census.Gov, viewed 01 September 2013, <http://www.census.gov/population/international/data/idb/ informationgateway.php>. 2. Tirtarahardja, G, Setyohadi, B, Weynand, LS & Zhou, Q 2006, ASBMR Lecture, Bone Mineral Density Reference Values for Indonesian Men and Women, American Society for Bone and Mineral Research Annual Meeting. 3. Rural population (% Of Total Population) in Indonesia 2013, Trading Economics, viewed 05 September 2013, <http://www.tradingeconomics.com/indonesia/ rural-population-wb-data.html>. 4. Hip fracture incidence map, International Osteoporosis Foundation, viewed 20 November 2013, <http://www.iofbonehealth.org/facts-and-statistics/hipfracture-incidence-map>. 5. Odén, A, McCloskey, E Johansson, H & Kanis, J 2013, Assessing the Impact of Osteoporosis on the Burden of Hip Fractures, Calcif Tissue Int, vol. 92, pp. 42 49. 6. Franken, J 2011, The Jakarta Post: Oford Business Group, <http://www. thejakartapost.com/news/2011/05/02/analysis-indonesia-the-health-nation. html>. 7. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: The 2008 Revision, viewed March 28, 2011, <http://esa.un.org/unpp>: Kanis, JA, data on file. RECOMMENDATIONS As previously stated, by 2050 the Indonesian population d over 50 years will have grown by 135% to 113 million and those d over 70 years will have grown by 294% to 40.8 million (Figure 2). These groups will account for over one-third of the total population with a lifespan averaging 80 years. These figures are a strong indication that Indonesia will feel the burden of osteoporosis in its ing population. Some recommendations that may bring relief to the health system and comfort to the elderly with osteoporosis include: Utilizing the eisting fracture registry for up-to-date analysis of the actual prevalence and incidence of fragility fractures to realize the true burden of osteoporosis. Promoting the implementation of fracture liaison services. Epanding the availability of DXA and osteoporosis health care providers to the more rural areas of the country. Encouraging the government to increase activities promoting osteoporosis care and treatment. 5